Medical Developments International Limited

OTCPK:MDDV.F Stock Report

Market Cap: US$42.1m

Medical Developments International Valuation

Is MDDV.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of MDDV.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: MDDV.F ($0.37) is trading below our estimate of fair value ($4.33)

Significantly Below Fair Value: MDDV.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDDV.F?

Key metric: As MDDV.F is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MDDV.F. This is calculated by dividing MDDV.F's market cap by their current revenue.
What is MDDV.F's PS Ratio?
PS Ratio1.6x
SalesAU$39.06m
Market CapAU$62.53m

Price to Sales Ratio vs Peers

How does MDDV.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MDDV.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.2x
MVRK Maverick Lifestyle
15.5xn/aUS$45.4m
MRMD MariMed
0.2x0.68%US$37.2m
IGC IGC Pharma
25.7x10.85%US$28.4m
NTRB Nutriband
23.3xn/aUS$53.0m
MDDV.F Medical Developments International
1.6x10.07%US$62.5m

Price-To-Sales vs Peers: MDDV.F is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (16.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does MDDV.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

74 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.4.7x8.8%
MDDV.F Medical Developments International
 1.6x10.07%US$42.13m
VTRS Viatris
1x1.84%US$14.81b
AMRX Amneal Pharmaceuticals
1.4x7.30%US$4.22b
MDDV.F 1.6xIndustry Avg. 4.7xNo. of Companies73PS0816243240+
74 CompaniesEstimated GrowthMarket Cap
Industry Avg.4.7x12.6%
MDDV.F Medical Developments International
 1.6x67.11%US$42.13m
No more companies

Price-To-Sales vs Industry: MDDV.F is good value based on its Price-To-Sales Ratio (1.6x) compared to the US Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is MDDV.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDDV.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MDDV.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MDDV.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.48
0%
62.88%US$2.42US$0.55n/a2
Jan ’27n/a
US$1.48
0%
62.88%US$2.42US$0.55n/a2
Dec ’26n/a
US$1.48
0%
62.88%US$2.42US$0.55n/a2
Nov ’26n/a
US$1.48
0%
62.88%US$2.42US$0.55n/a2
Oct ’26n/a
US$1.47
0%
64.68%US$2.42US$0.52n/a2
Sep ’26n/a
US$1.47
0%
64.68%US$2.42US$0.52n/a2
Aug ’26n/a
US$1.49
0%
65.01%US$2.47US$0.52n/a2
Jul ’26US$0.32
US$1.48
+361.55%
65.37%US$2.45US$0.51n/a2
Jun ’26n/a
US$1.48
0%
65.37%US$2.45US$0.51n/a2
May ’26n/a
US$1.48
0%
65.37%US$2.45US$0.51n/a2
Apr ’26n/a
US$1.32
0%
66.27%US$2.20US$0.45n/a2
Apr ’25n/a
US$1.51
0%
30.89%US$1.98US$1.04n/a2
US$1.56
Fair Value
76.2% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/20 22:08
End of Day Share Price 2026/01/09 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medical Developments International Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martyn JacobsBell Potter
Martyn JacobsCanaccord Genuity
Dan HurrenMST Financial Services Pty Limited